약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
Table. 5. RPN score of FMEA risk assessment for dual-release matrix tablet containing Sarpogrelate HCl
CQA Variables Hardness (kg) Drug contents (%) Drug release at 2 hr (%) Drug release at 24 hr (%)
API Purity Low (1*) Low (2) Low (1) Low (1)
Particle size Low (1) Low (1) Mid (4) Low (2)
Solubility Low (1) Low (1) Low (2) Low (2)
Binder Type Low (2) Low (2) Low (2) Low (2)
Viscosity Low (2) Low (2) Mid (4) Mid (4)
Ratio Low (2) Low (2) Mid (4) Mid (4)
Sustained release agent Type Low (1) Low (2) High (18) High (27)
Amount Low (1) Low (2) High (18) High (27)
Disintegrating agent Type Low (1) Low (2) Mid (6) Mid (6)
Amount Low (1) Low (2) Mid (6) Mid (9)
Lubricant Amount Mid (4) Low (2) Mid (4) Low (2)
Drying Time Mid (8) High (18) Mid (4) Mid (6)
Temperature Mid (8) High (18) Mid (4) Mid (6)
Tableting Pressure Mid (6) Low (2) Mid (4) Mid (12)

*RPN: Low (1~3), Middle (4~12), High (13~27)

Any variable above the RPN threshold of 13~27 was considered as potential high risk factor

Yakhak Hoeji 2024;68:252-68 https://doi.org/10.17480/psk.2024.68.4.252
© 2024 Yakhak Hoeji